Background: Implantable cardioverter-defibrillator (ICD) therapy is indicated for
A number of studies in the United Kingdom estimated the required ICD implant rate to meet National Institute for Health and Clinical Excellence (NICE) recommendations for primary and secondary prevention vary between 100 and 150/million/y. 7, 8 New
Zealand traditionally has had lower numbers of new implants/million population for ICD. 9, 10 In 2007, the ICD implant rate in New Zealand was 41/million population compared with Australia (145/million), the United States (577/million), and Western Europe (140/million). [9] [10] [11] [12] About 27% of implanted devices were for primary prevention indications. 9 Since then, there was a steady increase in ICD implant rates.
In 2013, there were 423 ICDs implanted in New Zealand. 13 The number of new implant/million population was still low at 95. 13 Several potential barriers to the optimal use of ICD therapy in eligible patients have been reported. [14] [15] [16] Affordability and capacity are of concern. 17 In New Zealand, there are approximately 12 000
hospital admissions each year; approximately 5500 patients are for heart failure (HF). 18 A large number of HF patients would potentially fulfill international guidelines criteria for these devices. Considering current workforce and funding constraints, the published 2010 New
Zealand guidelines have more restrictive recommendations. These guidelines currently recommend primary prevention ICD in patients with ICM of at least 1 month after acute MI or NICM present for at least 3 months, LVEF ≤ 30% measured ≥3 months after optimal HF treatment, and at least 3 months remote from any revascularization procedure. 19 
| METHODS
This was an observational study that described the medium-to long- 
| Statistical analysis
Baseline characteristics were summarized as either mean with standard deviation or frequency with percentage depending on the nature of the data. Comparisons between ICD and CRT-D were conducted using either the Wilcoxon rank-sum test, the chi-squared
test, or the two-sample Z test. Survival rates over time were depicted in Kaplan-Meier curves, and the differences between survival distributions were evaluated with the log-rank test. Univariate logistic regression was conducted to determine potential independent predictors of all-cause mortality, cardiovascular mortality, and HF mortality. Statistical analyses were performed using the statistical package SAS version 9.3 (SAS Institute, Cary, NC, USA). All P-values resulted from two-sided tests and a P-value of <.05 were considered statistically significant.
| RESULTS
A total of 404 procedures were performed in 385 HF patients. Mean The baseline characteristics of the patients are shown in Table 1 .
Compared to the CRT-D patients, ICD patients were younger (58.1 AE 11.9 years vs 61.1 AE 10.1, P = .019) and more likely to have ICM (49.1% vs 22.6%, P < .0001).
Five ICD patients were later upgraded to CRT-D. The mean time of upgrade was 3.2 AE 2.3 years. Indications for upgrade were a composition of worsening HF with deterioration in NYHA class, deterioration of LVEF, and/or widening of QRS duration on ECG.
| Complications
During the first 24 hours after implantation, there were 12 acute complications. These included lead dislodgements requiring intervention in 6 patients (5.2%) in the CRT-D group and 3 patients (1.5%) in the ICD group (P = .02) ( Table 2 ).
There were 5 device-pocket infections (1.29%) that required removal. Mean duration to infection was 1.79 AE 1.78 months. Mean duration to infection in ICD group was 1.68 AE 2.04 months, whereas it was 2.28 months in the CRT-D group (P = N.S).
| Device therapy
During the follow-up, 76 (19.7%) patients had received antitachycardia pacing (ATP) and 66 (17.1%) had appropriate ICD shocks. There was no difference in device therapy in the ICD and CRT-D patients (P = .80 and P = .14 for ATP and appropriate ICD shocks, respectively). There was no difference in the incidence of appropriate ICD therapy in ICM and NICM patients (P = .42 and P = .47, respectively). In our study, 35 (9.1%) patients received inappropriate shocks, most commonly due to atrial fibrillation (71.4%) and regular supraventricular tachyarrhythmias (25.7%). A small number experienced inappropriate therapy because of T-wave oversensing (2.9%).
T A B L E 1 Baseline characteristics of heart failure patients who received primary prevention ICD and CRT-D There was no difference between the two groups in the time to first inappropriate shocks (P = .74).
| Mortality
At the end of the follow-up, 67 (17.4%) patients had died. Of these deaths, 42 were classified as cardiovascular death, 8 deaths were due to malignancy and 8 from other noncardiac causes (P = .88).
The remainder 9 were classified as unspecified cause in the community. The 5-year all-cause and 5-year cardiovascular mortality rates were 14% and 9%, respectively.
Of the 42 cardiovascular deaths, 28 were due to HF and 12 deaths were attributable to MI, or cerebrovascular accidents. Only 2 were due to sudden arrhythmic death. These 2 patients had endstage HF for palliative care with slow ventricular arrhythmias below the detection rate programmed in their ICD for which no therapies were delivered. The 5-year HF mortality rate was 6%, whereas the 5-year sudden arrhythmic death rate was low at 0.3%.
There was no difference in cardiovascular or HF mortality rates in ICD and CRT-D patients ( Figure 1A,B) . For ICM and NICM patients, no difference in cardiovascular or HF survival was observed overtime (Figure 2A,B) .
Using univariant logistic regression analysis, Maori ethnicity, NYHA class III symptoms, and LVEF were significant predictors in all-cause and cardiovascular mortalities ( CRT-D patients, there was no difference in the mean duration to first HF hospitalization after implant (P = .40).
| Ventricular arrhythmia hospitalizations
There were 65 ventricular arrhythmia hospitalizations in 43 patients 
| DISCUSSION
Our study is a "real-world" description of the medium-to long-term outcomes of HF patients who received primary prevention ICD and CRT-D. In appropriately selected patients, there was a low incidence of arrhythmic death. CRT-D patients have lower hospitalization rates for both HF and ventricular arrhythmias. We have acceptable complication rates comparable to international published reports for the time. 20, 21 HF is an increasing problem in both developed and developing countries. The Framingham Heart Study showed that HF is associated with increased risk of SCD. 22 However, the most common mode of death in this group of patients remains progressive HF. In a subanalysis of the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial, pump failure (44.4%) was the most common mode of death followed by SCD (26.5%) in patients with advanced HF. 23 Our findings were Maori ethnicity was a significant predictor of all-cause and cardiovascular mortality in our study. In general, Maori are disproportionately represented in adverse health outcomes. 24 The device implantation rates were 14% (n = 54) in Maori, and only 5.2% . 25, 26 The HF mortality rate among Maori was more than twice as high as that of non-Maori (RR 2.36, CI 1.76-3.17). 25, 26 The reasons behind these inequalities are multifactorial including socioeconomic deprivation, cultural beliefs in health, and differences in adherence to guideline recommendation treatment. 27, 28 Among the 54 Maori patients who received these devices, 19 (35.2%) died during the follow-up period. HF was the cause of death in 26.3% of these patients. This suggests that more effective methods of optimizing HF therapy in Maori patients are required but the effective strategies to achieve this remain uncertain. Asians have lower incidence of HF, and this was reflected by the low number of device implantations. 29 Overall the perioperative risk is low for these devices, but the longer-term complications of these devices cannot be ignored. A recent meta-analysis reported a complication rate of 9.1% in 6433 patients with ICD implantation over 16 months. 21 Similarly, the National Cardiovascular Data Registry (NCDR) ICD registry reported 6.1 (CI, 6.0-6.2) ICD-related complications per 100 patient-years that required reoperation or hospitalization. 20 Our results suggest that while the implant rates are low, patients who had the devices implanted had slightly higher but acceptable rate of complications comparable to international published reports. Our success rate of LV lead implantation at first procedure was 89.7% compared to 97% in Cardiac Resynchronization Therapy Survey, there were no significant differences in clinical outcomes or complication rates between upgrades and de novo procedures. 36 Our patients were successfully upgraded at the initial attempt, and there were no acute complications.
It is also striking that the incidence hospitalization for both ventricular arrhythmias and HF was significantly lower in the CRT-D group suggesting that where appropriate this should be the device of choice.
| LIMITATIONS
There are several limitations in our study. This is a retrospective study where all the patients were retrospectively recruited but The New Zealand Cardiac Implanted Device Registry (ANZACS-QI 15) has recently been developed to collect information on all cardiac device implantations in New Zealand, which will aid quality improvement initiatives and to allow subsequent examination of equity of access to therapy, outcomes, and complications in a "realworld" view. The first description of data on new pacemaker implants from this Registry has been recently published. 38 We believe our study adds to the ANZACS-QI 15 data, giving a more detailed picture of current New Zealand practice with primary prevention ICD/CRT-D use in selected HF patients.
T A B L E 3 Univariant logistic regression analysis for all-cause mortality and cardiovascular mortality 
